Mobile

A Multi-center, Open-label Extension Study of the Safety and Tolerability of Long-term Administration of Oral CCI-779 (Temsirolimus) in Subjects with Relapsing Multiple Sclerosis Who Completed Study 3...

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-000171-18

A Multi-center, Open-label Extension Study of the Safety and Tolerability of Long-term Administration of Oral CCI-779 (Temsirolimus) in Subjects with Relapsing Multiple Sclerosis Who Completed Study 3066A2-210-WW

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the safety and tolerability of long-term therapy with 1 dose level of oral CCI-779 (temsirolimus; 8 mg/day) administered to subjects with relapsing-remitting or secondary progressive MS with relapses who completed study 3066A2-210-WW.

Critère d'inclusion

  • Multiple Sclerosis (Relapsing-remitting MS and Secondary progressive MS with relapses)

Liens